Ainos Issues Mid-Year Business Update Letter to Shareholders; Ramping Up Marketing Of VELDONA Pet And Aiming To Complete Clinical Trials In Taiwan Of Its Flagship AI Nose-Powered POCT By The End Of 2023
Portfolio Pulse from Happy Mohamed
Ainos, Inc. is ramping up marketing for its VELDONA Pet health supplements and aims to complete clinical trials for its AI Nose-powered POCT by the end of 2023. The company expects VELDONA Pet revenues to reach $20 million in 2024 and is targeting new markets for expansion.
June 27, 2023 | 12:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ainos is increasing marketing efforts for VELDONA Pet and targeting completion of AI Nose-powered POCT clinical trials by 2023, with expected revenues of $20 million in 2024.
Ainos' increased marketing efforts for VELDONA Pet and the completion of AI Nose-powered POCT clinical trials by 2023 are expected to drive revenue growth. The company is targeting new markets for expansion, which could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100